A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Erlotinib; Sorafenib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2011 Status changed from active, no longer recruiting to completed.
    • 03 May 2011 Planned End Date changed from 1 Jun 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 27 Jan 2010 Planned end date changed from 1 Jan 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top